CONGENITAL BLEEDING DISORDER
Clinical trials for CONGENITAL BLEEDING DISORDER explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL BLEEDING DISORDER trials appear
Sign up with your email to follow new studies for CONGENITAL BLEEDING DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with hemophilia b: experimental drug shows promise in controlling bleeds
Disease control CompletedThis study tested a new medicine (NNC-0156-0000-0009) in 25 children with hemophilia B, a bleeding disorder. The goal was to see if the drug is safe and helps prevent or control bleeding episodes. Children received the drug regularly, and researchers tracked how many bleeds occur…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New hope for kids with hemophilia b: Long-Lasting clotting factor shows promise
Disease control CompletedThis study tested a new medicine called nonacog beta pegol (N9-GP) in 54 children under 6 with hemophilia B, a bleeding disorder. The drug is a long-acting clotting factor given regularly to prevent bleeding episodes. The main goal was to see if the children's immune systems woul…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for young kids with severe bleeding disorder: safer clotting factor studied
Disease control CompletedThis study tested a new medicine called N8-GP (turoctocog alfa pegol) in 124 young children under 6 with severe haemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The medicine is a longer-acting clotting factor…
Matched conditions: CONGENITAL BLEEDING DISORDER
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 19, 2026 11:59 UTC